New Search

If you are not happy with the results below please do another search

Generic filters

50 search results for:


Provention Bio Gets Another Shot at Delaying Diabetes

Provention Bio is resubmitting a Biologics License Application (BLA) for teplizumab, a drug intended to delay the onset of Type 1 diabetes (T1D) in at-risk individuals, following a Type B pre-BLA resubmission meeting with the U.S. Food and Drug Administration.